Cancer Treatment Today

FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with  iron overload form transfusions due to thalassemia syndromes when current chelation therapy, most commonly Exjade,  is inadequate. The approval in second line is reasonable both because the studies for approval were done in second line and because Ferroprox may be inferior to Exjade in first line (Cemak et al). This is not an innocuous drug; the most serious

Anemia is common in young women and is usually due to iron deficiency. If anemia has a slower, subacute onset, younger patients without significant medical problems can tolerate low hemoglobin levels. Often times, however, in addition to being anemic for some time, young women may have recently bled. In this situation there is less time for the body to become used to the low red cell levels and a moderate anemia may cause symptoms, such as, shortness